TABLE 3.
Baseline Signs of Inflammation and Disease Characteristics.
| Characteristic | Study |
Total | |
|---|---|---|---|
| PEACHTREE | AZALEA | ||
| Time since diagnosed, wk | (n = 160) | (n = 38) | (N = 198) |
| Mean (SE) | 37.3 (4.03) | 35.0 (7.79) | 36.9 (3.58) |
| Median | 16.4 | 15.2 | 15.8 |
| Minimum, maximum | 0, 316 | 0, 242 | 0, 316 |
| Presence of | |||
| Anterior uveitis | 41 (25.6) | 12 (31.6) | 53 (26.8) |
| Intermediate uveitis | 57 (35.6) | 15 (39.5) | 72 (36.4) |
| Posterior uveitis | 35 (21.9) | 10 (26.3) | 45 (22.7) |
| Panuveitis | 52 (32.5) | 10 (26.3) | 62 (31.3) |
| Onset type | |||
| Sudden | 35 (21.9) | 16 (42.1) | 51 (25.8) |
| Insidious | 125 (78.1) | 20 (52.6) | 145 (73.2) |
| Unknown | 0 | 2 (5.3) | 2 (1.0) |
| Duration | |||
| Limited, ≤3 months | 27 (16.9) | 5 (13.2) | 32 (16.2) |
| Persistent, >3 months | 133 (83.1) | 31 (81.6) | 164 (82.8) |
| Unknown | 0 | 2 (5.3) | 2 (1.0) |
| Course | |||
| Acute | 11 (6.9) | 1 (2.6) | 12 (6.1) |
| Recurrent | 48 (30.0) | 11 (28.9) | 59 (29.8) |
| Chronic | 101 (63.1) | 24 (63.2) | 125 (63.1) |
| Unknown | 0 | 2 (5.3) | 2 (1.0) |
| Anterior chamber cells | |||
| 0 | 87 (54.4) | 17 (44.7) | 104 (52.5) |
| 0.5+ | 34 (21.3) | 13 (34.2) | 47 (23.7) |
| 1+ | 22 (13.8) | 6 (15.8) | 28 (14.1) |
| 2+ | 11 (6.9) | 2 (5.3) | 13 (6.6) |
| 3+ | 6 (3.8) | 0 | 6 (3.0) |
| 4+ | 0 | 0 | 0 |
| Anterior chamber flare | |||
| 0 | 105 (65.6) | 27 (71.1) | 132 (66.7) |
| 0.5+ | 0 | 1 (2.6) | 1 (0.5) |
| 1+ | 40 (25.0) | 4 (10.5) | 44 (22.2) |
| 2+ | 15 (9.4) | 2 (5.3) | 17 (8.6) |
| 3+ | 0 | 4 (10.5) | 4 (2.0) |
| 4+ | 0 | 0 | 0 |
| Vitreous haze | |||
| 0 | 40 (25.0) | 17 (44.7) | 57 (28.8) |
| 0.5+ | 36 (22.5) | 5 (13.2) | 41 (20.7) |
| 1+ | 51 (31.9) | 9 (23.7) | 60 (30.3) |
| 1.5+ | 3 (1.9) | 1 (2.6) | 4 (2.0) |
| 2+ | 28 (17.5) | 4 (10.5) | 32 (16.2) |
| 3+ | 2 (1.3) | 1 (2.6) | 3 (1.5) |
| 4+ | 0 | 1 (2.6) | 1 (0.5) |
AZALEA = Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients with Non-Infectious Uveitis; PEACHTREE = A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Patients with Macular Edema associated with Non-Infectious Uveitis; SE = standard error of the mean.
Note: Data are shown as n (%) unless indicated otherwise.